KappaMab

Drug Profile

KappaMab

Alternative Names: IST-1097; MDX-1097; MDX-1097 (kappa)

Latest Information Update: 08 Sep 2016

Price : $50

At a glance

  • Originator Immune System Therapeutics; Medarex
  • Developer HaemaLogiX
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Natural killer cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Multiple myeloma

Most Recent Events

  • 08 Sep 2016 HaemaLogiX plans a phase IIb trial for Multiple myeloma (Second-line therapy, Combination therapy) in Australia (ACTRN12616001164482p)
  • 14 Aug 2015 Phase-II development for Multiple myeloma is ongoing in Australia
  • 04 Mar 2015 HaemaLogiX acquires the assets of Immune System Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top